OSA patients receiving airways treatment had a median level of gp130 that was much higher than that in untreated patients (p = 2.8 × 10−13), a median level indistinguishable from that observed in the younger control group (p = 0.87, Fig. 1a, Table 2). This evidence concerns the gene IL6ST and obstructive sleep apnea syndrome.